MDXL — Medixall Share Price
- $0.00m
- $2.56m
- $0.06m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -11524.23% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0 | 0 | n/a | 0.01 | 0.06 | n/a | n/a | 21.67% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
MediXall Group, Inc. is a technology company. The Company is engaged in delivering products and services to help consumers learn, decide, and pay for healthcare in ways that complement relationships with trusted doctors. With Health Karma, it has created a membership model that provides consumers with convenience and access to whenever and wherever, while driving down overall healthcare costs. It provides its members access to licensed healthcare providers across a spectrum of care through copay virtual primary, urgent, and behavioral care, as well as significant discounts to prescriptions, dental care, eye care, hearing and medical equipment. For employers, Its Health Karma membership offers a comprehensive way for them to offer supplemental health benefits to all of their employees, including part-time and gig workers. The Company’s subsidiaries include Medixaid, Inc., MediXall.com, Inc. and Health Karma, Inc.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- December 21st, 1998
- Public Since
- January 16th, 2003
- No. of Shareholders
- 923
- No. of Employees
- 17
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 130,487,491
- Address
- 2598 E. SUNRISE BLVD., SUITE 2104, FT LAUDERDALE, 33304
- Web
- https://www.medixallgroup.com/
- Phone
- +1 9544404678
- Auditors
- Hacker, Johnson & Smith PA
Upcoming Events for MDXL
Similar to MDXL
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
As of Today at 18:14 UTC, shares in Medixall are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Medixall last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Medixall share price has underperformed the S&P500 Index by -100% over the past year.
There is no consensus recommendation for this security.
Medixall does not currently pay a dividend.
Medixall does not currently pay a dividend.
Medixall does not currently pay a dividend.
To buy shares in Medixall you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Medixall had a market capitalisation of $0.00m.
Here are the trading details for Medixall:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MDXL
Based on an overall assessment of its quality, value and momentum Medixall is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medixall. Over the past six months, its share price has underperformed the S&P500 Index by -99.86%.
As of the last closing price of $0.00, shares in Medixall were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medixall PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medixall's management team is headed by:
- Neil Swartz - CHM
- Timothy Hart - CFO
- Noel Guillama - IND